{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:19:46Z","timestamp":1791443986125,"version":"4.3.3"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.leukres.2026.108204","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T15:46:56Z","timestamp":1773589616000},"page":"108204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapy"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-9653","authenticated-orcid":false,"given":"Alexander","family":"Ambinder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Levis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-3098","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Pratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108204_bib1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s12185-008-0184-2","article-title":"Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies","volume":"88","author":"Auberger","year":"2009","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108204_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.21776","article-title":"Invasive fungal disease in patients treated for newly diagnosed acute leukemia","volume":"85","author":"Hammond","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108204_bib3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108204_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.2000.02014.x","article-title":"Towards a targeted, risk-based, antifungal strategy in neutropenic patients","volume":"110","author":"Prentice","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108204_bib5","first-page":"81","article-title":"Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data","volume":"25","author":"Yu","year":"2014","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.leukres.2026.108204_bib6","first-page":"703","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.leukres.2026.108204_bib7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108204_bib8","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","article-title":"Beat-AML 2024 ELN\u2013refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy","volume":"8","author":"Hoff","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108204_bib9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108204_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108204_bib11","unstructured":"Abbvie, Inc. Venetoclax [package insert]. U.S. Food and Drug Administration website., (n.d.). \u3008https:\/\/docs.google.com\/viewer?url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F208573s013lbl.pdf\u3009 (accessed November 1, 2020)."},{"key":"10.1016\/j.leukres.2026.108204_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: Introducing the E-Value","volume":"167","author":"Van Der Weele","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.leukres.2026.108204_bib13","doi-asserted-by":"crossref","first-page":"E422","DOI":"10.1002\/ajh.26707","article-title":"Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study","volume":"97","author":"Jonas","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108204_bib14","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108204_bib15","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2026.108204_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hon.2964","article-title":"Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-na\u00efve acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"40","author":"Brackman","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2026.108204_bib17","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.286062","article-title":"Exposure toxicity of venetoclax in acute myeloid leukemia patients in the real-life setting: impact of high exposure on delayed neutropenia","author":"Puisset","year":"2024","journal-title":"Haematologica"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T03:59:59Z","timestamp":1776225599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":17,"alternative-id":["S0145212626000482"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108204","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108204"}}